OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
VERU$2.0959

Veru Inc

Biotechnology & Medical ResearchVerified

Veru Inc has a market capitalization of $33.55 million and a price-to-book ratio of 0.74, indicating that the company is trading at a discount to its book value. The company's liquidity position is strong, with a current ratio of 4.72 and $34.74 million in cash and equivalents, which provides a buffer against short-term obligations. The debt-to-equity ratio of 0.22 suggests a conservative capital structure with limited leverage. The company's profitability metrics are negative, with a return on equity of -22.18% and a return on assets of -13.96%, indicating that it is not generating returns for shareholders or effectively utilizing its assets. The operating and net losses of $8.89 million and $10.03 million, respectively, highlight the company's ongoing financial challenges. These results are below the industry norms for profitability and returns, which typically require positive ROE and ROA figures for long-term sustainability. Veru Inc's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the company's risk profile from a segment or regional perspective. The absence of detailed segment reporting limits the ability to evaluate the performance of different product lines or geographic regions. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and free cash flows of $11.67 million and $8.68 million, respectively, indicate that the company is not generating sufficient cash to fund operations or expansion. The capital expenditure of $40,660 is minimal, suggesting limited investment in long-term growth initiatives. The risk assessment for Veru Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's strong cash position and low debt levels reduce the likelihood of near-term financial distress. However, the ongoing net losses and negative cash flows pose long-term sustainability risks that could necessitate future equity or debt financing. Recent events and filings for Veru Inc do not provide specific details on recent developments, but the company's financial performance and analyst estimates suggest a mixed outlook. The mean price target of $24.50 and a strong buy recommendation from analysts indicate some optimism about the company's future. However, the current financial metrics and operational performance suggest that significant improvements are needed to justify such high price targets.

30-day price · VERU(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyVeru Inc
TickerVERU.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Veru Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for women's health and urology.

Classification. Veru Inc is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector with a classification confidence of 0.92.

Veru Inc has a market capitalization of $33.55 million and a price-to-book ratio of 0.74, indicating that the company is trading at a discount to its book value. The company's liquidity position is strong, with a current ratio of 4.72 and $34.74 million in cash and equivalents, which provides a buffer against short-term obligations. The debt-to-equity ratio of 0.22 suggests a conservative capital structure with limited leverage. The company's profitability metrics are negative, with a return on equity of -22.18% and a return on assets of -13.96%, indicating that it is not generating returns for shareholders or effectively utilizing its assets. The operating and net losses of $8.89 million and $10.03 million, respectively, highlight the company's ongoing financial challenges. These results are below the industry norms for profitability and returns, which typically require positive ROE and ROA figures for long-term sustainability. Veru Inc's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the company's risk profile from a segment or regional perspective. The absence of detailed segment reporting limits the ability to evaluate the performance of different product lines or geographic regions. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and free cash flows of $11.67 million and $8.68 million, respectively, indicate that the company is not generating sufficient cash to fund operations or expansion. The capital expenditure of $40,660 is minimal, suggesting limited investment in long-term growth initiatives. The risk assessment for Veru Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's strong cash position and low debt levels reduce the likelihood of near-term financial distress. However, the ongoing net losses and negative cash flows pose long-term sustainability risks that could necessitate future equity or debt financing. Recent events and filings for Veru Inc do not provide specific details on recent developments, but the company's financial performance and analyst estimates suggest a mixed outlook. The mean price target of $24.50 and a strong buy recommendation from analysts indicate some optimism about the company's future. However, the current financial metrics and operational performance suggest that significant improvements are needed to justify such high price targets.
Key takeaways
  • Veru Inc is trading at a significant discount to its book value, with a price-to-book ratio of 0.74.
  • The company has a strong liquidity position, with a current ratio of 4.72 and $34.74 million in cash and equivalents.
  • Veru Inc is experiencing negative profitability, with a return on equity of -22.18% and a return on assets of -13.96%.
  • Analysts have a generally positive outlook, with a mean price target of $24.50 and a strong buy recommendation.
  • The company's financial performance and operational metrics suggest a need for significant improvements to justify the high price targets.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income-$8.9M
Net income-$10.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$11.7M
CapEx-$40.7k
Free cash flow-$8.7M
Total assets$71.8M
Total liabilities$26.6M
Total equity$45.2M
Cash & equivalents$34.7M
Long-term debt$9.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$61.3M$13.0M$7.4M$7.2M
FY-3$39.4M-$83.5M-$84.0M-$84.6M
FY-2$16.3M-$93.8M-$93.2M-$93.5M
FY-1-$36.2M-$37.8M-$35.2M
FY0-$16.1M-$22.7M-$15.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$178.1M$152.3M$122.4M
FY-3$135.4M$82.8M$80.2M
FY-2$50.0M$19.7M$9.6M
FY-1$60.4M$32.3M$24.9M
FY0$29.8M$18.3M$15.8M
PeriodOCFCapExFCFSBC
FY-4-$15.6M-$376.6k$7.2M
FY-3-$47.5M-$733.0k-$84.6M
FY-2-$88.0M-$665.7k-$93.5M
FY-1-$21.7M-$158.3k-$35.2M
FY0-$30.0M-$1.1k-$15.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7-$8.9M-$10.0M-$8.7M
FQ-6-$10.5M-$11.0M-$10.3M
FQ-5-$9.3M-$8.5M-$8.5M
FQ-4-$1.6M-$8.9M-$1.7M
FQ-3-$8.1M-$7.9M-$7.8M
FQ-2-$7.5M-$7.3M-$7.3M
FQ-1$1.2M$1.5M$1.3M
FQ0-$5.4M-$5.3M-$5.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$71.8M$45.2M$34.7M
FQ-6$64.6M$37.6M$29.2M
FQ-5$60.4M$32.3M$24.9M
FQ-4$39.8M$26.6M$26.6M
FQ-3$32.7M$21.0M$20.0M
FQ-2$27.3M$15.3M$15.0M
FQ-1$29.8M$18.3M$15.8M
FQ0$47.6M$37.1M$33.0M
PeriodOCFCapExFCFSBC
FQ-7-$11.7M-$40.7k-$8.7M
FQ-6-$17.3M-$95.3k-$10.3M
FQ-5-$21.7M-$158.3k-$8.5M
FQ-4-$11.3M-$1.1k-$1.7M
FQ-3-$19.1M-$1.1k-$7.8M
FQ-2-$24.6M-$1.1k-$7.3M
FQ-1-$30.0M-$1.1k$1.3M
FQ0-$6.2M$0.00-$5.3M
Valuation
Market price$2.09
Market cap$33.5M
Enterprise value$8.5M
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B0.7
P/Tangible book0.7
Tangible book$45.2M
Net cash$25.0M
Current ratio4.7
Debt/Equity0.2
ROA-14.0%
ROE-22.2%
Cash conversion1.2%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricVERUActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity22.0%9.3% medp25 0.1% · p75 43.8%above median
Observations
IR observations
Mean price target24.50 USD
Median price target24.50 USD
High price target25.00 USD
Low price target24.00 USD
Mean recommendation1.50 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-1.20 USD
Last actual EPS-1.55 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-17 02:03 UTC#a644ad3a
Market quoteclose USD 2.28 · shares 0.02B diluted
no public URL
2026-05-17 02:03 UTC#5b164ee8
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 22:09 UTCJob: ff45aa6b